Sigmoid Biotechnologies, an Irish Drug Delivery Systems Development SME established in 2003, has developed a novel oral controlled release technology, Liquid and Emulsion Drug Delivery System or LEDDS. LEDDS enables the controlled release of difficult to formulate drugs that are optimally formulated in various liquid or emulsion formats. To date, Sigmoid has demonstrated that LEDDS is effective in delivering small molecule as well as cyclic peptide drugs.
Going forward, Sigmoid has recognised that a modified LEDDS format would have significant potential to orally delivery biopharmaceutical drugs such as peptides and proteins. The LEDDS modification will require that Sigmoid strengthens its knowledge of lipid and emulsion formulation technologies, bioadhesive polymer synthesis and development as well as establishing an in-house intelligent in vitro drug formulation screening technology. To facilitate this development, a multidisciplinary work programme has been planned and will involve Sigmoid collaborating with and transferring personnel amongst four EU laboratories based in Poland, Italy, Germany and Ireland, each recognised as world class in their respective fields.
Developing an integrated LEDDS-enabled oral biopharmaceutical delivery system will lead to the development of significant patent protection and increase Sigmoid's competitive position in the drug delivery industry in general and in the area of biopharmaceutical delivery in particular. Sigmoid's partners will benefit from acquiring knowledge of LEDDS technology as well as industrial training in a cGMP facility. Also, visiting scientists will have opportunities to publish and present the work carried out as well as being encouraged to file patents.
Call for proposal
See other projects for this call